Skip to main content
SpringerLink
Log in

Metabolic Issues in Schizophrenic Patients Receiving Antipsychotic Treatment

  • Original Article
  • Published:
Indian Journal of Clinical Biochemistry Aims and scope Submit manuscript

Abstract

Schizophrenia is a psychotic disorder with a complex pathophysiology and requires treatment that includes long term administration of antipsychotics that is said to be associated with metabolic syndrome. This study was designed to evaluate the impact of seven different antipsychotics prescribed to schizophrenic patients, on development of metabolic syndrome in the patients. A total of 210 patients with schizophrenia (30 patients in each drug therapy group) were recruited according to ICD-10 criteria and were assigned to receive the drug for 16 weeks. Measurement of anthropometric (body weight, waist circumference, blood pressure) and biochemical parameters (glucose, insulin, HOMA-IR, triglycerides, LDL, HDL) was done and the patients were subjected to ATP-III defined criteria for metabolic syndrome. Patients undergoing treatment with olanzapine were more prone to metabolic syndrome as the drug induces weight gain after 16 weeks of treatment. It also induces dyslipidemia (P < 0.001) and hyperglycemia (P < 0.01). Clozapine was found to be second most potent drug in inducing metabolic syndrome as the weight in clozapine treated patients increased after 16 weeks, along with a significant increase in glycemic (P < 0.001) and lipid parameters (P < 0.01). Aripriazole and amisulphride are comparatively safer drugs as their role in inducing metabolic abnormalities in schizophrenic patients was insignificant, although the impact of long term administration of these drugs needs to be explored. It is clear from the study that antipsychotic treatment induces metabolic syndrome so, it becomes important that the metabolic and cardiovascular risk factors should be surveillance regularly in schizophrenic patients undergoing antipsychotic treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Gaur N, Gautam S, Gaur M, Sharma P, Dadheech G, Mishra S. The biochemical womb of schizophrenia: a review. IJCB. 2008;23(4):307–27.

    CAS  PubMed Central  PubMed  Google Scholar 

  2. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156(11):1686–96.

    CAS  PubMed  Google Scholar 

  3. Kaplan SI, Sadock BJ. Schizophrenia comprehensive textbook of psychiatry, vol. 1. 6th ed. Baltimore: Williams and Wilkins; 1989. p. 699–815.

    Google Scholar 

  4. Garry R. Schizophrenia, antipsychotics, and the metabolic syndrome: is there a silver lining? Am J Psychiatry. 2006;163:1132–4.

    Article  Google Scholar 

  5. Homel P, Casey D, Allison DB. Changes in body mass index for individuals with and without schizophrenia 1987–1996. Schizophr Res. 2002;55(3):277–84.

    Article  PubMed  Google Scholar 

  6. Davidson S, Judd F, Jolley D, Hocking B, Thompson S, Hyland B. Cardiovascular risk factors for people with mental illness. Aust N Z J Psychiatry. 2001;35(2):196–202.

    Article  CAS  PubMed  Google Scholar 

  7. Deglin JH, Vallerand AH, Sanoski CA. Davis drug guide. 10th ed. Philadelphia: FA Davis; 2007.

    Google Scholar 

  8. Masand PS. Relative weight gain among antipsychotics. J Clin Psychiatry. 1999;60:706–8.

    Article  CAS  PubMed  Google Scholar 

  9. Trinder P. Determination of glucose in blood using glucose oxidase with an alternative glucose acceptor. Ann Clin Biochem. 1969;6:24–7.

    Article  CAS  Google Scholar 

  10. Herbert K. Lipids: in clinical chemistry. In: Kaplan LA, Pesce AJ, editors. Theory, analysis and co-relation. Toronto: CV Mosby; 1984. p. 1182–230.

    Google Scholar 

  11. Okada M, Matsui H, Ito Y, Fujiwara A. Direct measurement of HDL cholesterol: method eliminating apolipoprotein E-rich particles. J Clin Lab Anal. 2001;15:223–9.

    Article  CAS  PubMed  Google Scholar 

  12. Yang X, Guo A, Wu L, Deng A, Yang H. Chemiluminiscent immunoassay for insulin. Hua Xi Yi Ke Da Xue Xue Bao. 1991;22(3):259–61.

    CAS  PubMed  Google Scholar 

  13. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Teacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia. 1985;28:412–9.

    Article  CAS  PubMed  Google Scholar 

  14. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of metabolic syndrome. Circulation. 2005;112:2735–52.

    Article  PubMed  Google Scholar 

  15. Osby U, Correia N, Brandt L. Mortality and causes of death in schizophrenia in Stockholm Country Sweden. Schizophr Res. 2000;45:21–8.

    Article  CAS  PubMed  Google Scholar 

  16. Heiskanen T, Niskanen L, Lytikkanen R, Saarinen PL, Hintikka J. Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry. 2003;64:575–9.

    Article  PubMed  Google Scholar 

  17. Elligord VL, Miller DD, Taylor SF. Dietary lifestyle and pharmacogenetic factors associated with arteriole endothelial dependent vasodilatations in schizophrenic patients. Schizopher Res. 2008;98:47–54.

    Article  Google Scholar 

  18. Bray GA. Afferent signals regulating food intake. Proc Nutr Soc. 2000;59:373–84.

    Article  CAS  PubMed  Google Scholar 

  19. Silvestee JS, Prous J. Association of genetic variant of histamine H1 and muscarinic M3 receptors with BMI and HbA1c values in patients with antipsychotic medication. Exp Clin Pharmacol. 2005;27:289–304.

    Google Scholar 

  20. Dweyer DS, Donohoe D. Induction of hyperglycemia in mice with atypical antipsychotic drug that inhibit glucose uptake. Pharmacol Biochem Behav. 2003;75:255–60.

    Article  Google Scholar 

  21. Walton C, Lees B, Crook D. Body fat distribution rather than overall adiposity, influences serum lipids and lipoprotein in healthy men independently of age. Am J Med. 1995;99:459–64.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medanta, The Medicity, Gurgaon, Haryana, India

    Aditi Gupta

  2. Department of Biochemistry, NIMS Medical College, Jaipur, Rajasthan, India

    Gora Dadheech

  3. Department of Biochemistry, S.M.S. Medical College, Jaipur, Rajasthan, India

    Dharamveer Yadav

  4. Department of Biochemistry, All India Institute of Medical Sciences, Jodhpur, 342005, Rajasthan, India

    Praveen Sharma

  5. Gautam Institute of Behavioral Sciences and Alternative Medicine, Jaipur, Rajasthan, India

    Shiv Gautam

Authors
  1. Aditi Gupta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gora Dadheech
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dharamveer Yadav
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Praveen Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shiv Gautam
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Praveen Sharma.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gupta, A., Dadheech, G., Yadav, D. et al. Metabolic Issues in Schizophrenic Patients Receiving Antipsychotic Treatment. Ind J Clin Biochem 29, 196–201 (2014). https://doi.org/10.1007/s12291-013-0415-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12291-013-0415-z

Keywords

Search

Navigation